Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 2,085 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: HIV-1 Infection
Interventions: BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more

Conditions: HIV Infections
Interventions: VH4524184, Itraconazole, Rifabutin, Phenytoin, Metformin, Digoxin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Chronic Hepatitis B
Interventions: Tenofovir DF, TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 5
States / cities: Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 2 more

Conditions: Schizophrenia
Interventions: Brexpiprazole (OPC-34712); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Little Rock, Arkansas • Culver City, California • Orange, California + 7 more

Conditions: Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration
Interventions: GEM103; Biological
Lead sponsor: Gemini Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 12
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 8 more

Conditions: Alcohol Dependence
Interventions: Mirtazapine, Quetiapine fumarate extended release (Quetiapine XR); Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Bedford, New Hampshire • Hanover, New Hampshire

Conditions: Hypertension
Interventions: Ambrisentan 5 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Moderate to Severe Chronic Plaque-Type Psoriasis
Interventions: AIN457 150 mg, AIN457 300 mg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 28
States / cities: Fresno, California • Pasadena, California • San Francisco, California + 24 more

Conditions: Breast Cancer
Interventions: Eribulin Mesylate, Ixabepilone; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 50
States / cities: Sedona, Arizona • Hawthorne, California • Los Angeles, California + 39 more

Conditions: Multiple Sclerosis
Interventions: Fampridine-SR b.i.d. (Twice Daily); Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 17 more

Conditions: Photosensitive Epilepsy
Interventions: Fenfluramine Hydrochloride; Drug
Lead sponsor: Elizabeth Anne Thiele; Other
Eligibility: 4 Years to 25 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure
Interventions: Zepatier; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 140
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: ABT-089; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 12
States / cities: Lafayette, California • Jacksonville, Florida • Orlando, Florida + 9 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 48
States / cities: Phoenix, Arizona • Laguna Hills, California • Palo Alto, California + 39 more

Conditions: Chronic Pain
Interventions: tramadol ER; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Parkinson's Disease
Interventions: Istradefylline ( KW-6002); Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions: ZYNRELEF 200Mg-6Mg Extended-Release Solution; Drug
Lead sponsor: Dr. Yannis Raftopoulos; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Holyoke, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: MT-1186; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Phoenix, Arizona • Rogers, Arkansas • Aurora, Colorado + 9 more

Conditions: Pharmacokinetics
Interventions: Naproxen Sodium, (BAY H6689), Naprelan, (BAY H6689); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV-1 Infection
Interventions: FTC/RPV/TAF, FTC/RPV/TDF Placebo, FTC/RPV/TDF, FTC/RPV/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 75
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 56 more

Conditions: Crohn's Disease, IBD
Interventions: Brazikumab Induction Dose, Brazikumab Maintenance Dose; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Lincoln, California • Clearwater, Florida • Kissimmee, Florida + 6 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
Interventions: Rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 6
States / cities: San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost; Drug
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Artesia, California • La Jolla, California • Newport Beach, California + 7 more

Search by objective public record fields.

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency

A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).

Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

Open-label Extension Study of Brazikumab in Crohn's Disease

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product